Following a regulatory update, Japanese speciality pharma company Kyowa Kirin (TYO: 4151) has announced it will pull the plug on its small molecule bardoxolone methyl.
Codenamed RTA 402, the compound was licensed from Reata Pharmaceuticals (Nasdaq: RETA), an American company, in 2009.
Reata stock has fallen around 15% since the announcement was made, but that was likely to do with a setback for its Skyclarys (omavaloxolone) announced a day earlier.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze